Related Experiment Video

Updated: Aug 15, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

[Cardio-protection and cardio-reparation in systemic arterial hypertension]

F Vallés Belsué1, M Anguita Sánchez

  • 1Servicio de Cardiología, Hospital Reina Sofía, Córdoba.

Revista Espanola De Cardiologia
|January 1, 1997
PubMed

Insights

Left ventricular hypertrophy, a risk factor for cardiovascular events, involves heart remodeling. Therapeutic goals include normalizing heart structure and function, not just blood pressure.

Area of Science:

  • Cardiovascular Medicine
  • Cardiac Pathophysiology
  • Hypertension Research

Context:

  • Systemic hypertension frequently leads to left ventricular hypertrophy (LVH).
  • LVH is a significant independent predictor of adverse cardiovascular outcomes.
  • Cardiac remodeling, encompassing changes in myocardial structure and function, is central to LVH pathogenesis.

Purpose:

  • To explore the mechanisms of cardiac remodeling in systemic hypertension.
  • To define the concepts of cardioreparation and cardioprotection.
  • To highlight the therapeutic goal of achieving normal cardiac structure and function alongside blood pressure control.

Summary:

  • Left ventricular hypertrophy in systemic hypertension results from increased myocytic and non-myocytic compartments, leading to cardiac remodeling.
  • Hormonal factors, such as renin-angiotensin-aldosterone system activation, contribute to remodeling beyond elevated pressure.
  • Functional impairments, including diastolic dysfunction and later dilatation, stem primarily from fibrosis.

Impact:

  • Understanding remodeling mechanisms is crucial for developing targeted therapies.
  • Cardioreparation aims to reverse structural and functional deficits caused by remodeling.
  • Cardioprotection strategies focus on preventing the development of cardiac remodeling.
  • The ultimate therapeutic aim is to restore both structural and functional cardiac integrity in hypertensive patients.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases04:59

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases

Published on: June 20, 2025

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...